Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-05-20
2008-05-20
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000, C530S389700, C436S064000
Reexamination Certificate
active
10117030
ABSTRACT:
The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
REFERENCES:
patent: 5324634 (1994-06-01), Zucker
patent: 5356817 (1994-10-01), Cole
patent: 5643752 (1997-07-01), Hawkins et al.
patent: 7108983 (2006-09-01), Holten-Andersen et al.
patent: 2002/0012950 (2002-01-01), Nielsen et al.
patent: 2004/0014190 (2004-01-01), Lawrence et al.
patent: 2004/0105862 (2004-06-01), Pan et al.
patent: 2004/0157278 (2004-08-01), Astle et al.
patent: 2006/0014224 (2006-01-01), Brunner et al.
patent: 2006/0154245 (2006-07-01), Hessel et al.
patent: 2007/0020707 (2007-01-01), Holtan-Andersen et al.
patent: 1236102 (1999-11-01), None
patent: PA1999 00476 (1999-04-01), None
patent: 1171771 (2000-10-01), None
patent: 1381631 (2002-10-01), None
patent: 1382969 (2004-01-01), None
patent: 1 439 393 (2004-07-01), None
patent: 08136548 (1996-05-01), None
patent: WO 93/20447 (1993-10-01), None
patent: WO 9738314 (1997-10-01), None
patent: WO 00/20860 (2000-04-01), None
patent: WO 00/62070 (2000-10-01), None
patent: WO 00/62070 (2000-10-01), None
patent: 01/11359 (2001-02-01), None
patent: WO 02/34776 (2002-05-01), None
patent: WO 02/44736 (2002-06-01), None
patent: 02/086085 (2002-10-01), None
patent: WO 02/086085 (2002-10-01), None
patent: WO 03/000671 (2003-01-01), None
patent: WO 03/060522 (2003-02-01), None
patent: WO 03/087830 (2003-10-01), None
patent: WO 2004/029627 (2004-04-01), None
patent: WO 2005/010213 (2005-02-01), None
Simpson RA, et al. Colorectal Dis. 2000; 2: 100-5.
Pellegrini P, et al. Cancer Immunol Immunother. Sep. 2000; 49 (7): 388-94.
Leroy V, et al. Am J Gastroenterol. Feb. 2004; 99 (2): 271-6.
Matsuura E, et al. J Neurol Sci. 2000; 173: 45-52.
Jinnin M, et al. Clin Exp Rheumatol. Jul.-Aug. 2002; 20 (4): 539-42.
Katoh N, et al. Clin Exp Immunol. 2002 127:283-8.
Tsavellas G, et al. Br J Surg. Oct 2001; 88 (10): 1307-20.
Liefers GJ, et al. Histopathology. May 1999; (5): 385-90.
Lacroix J, et al. Sem Surg Oncol. 2001; 20: 252-64.
Calaluce R, et al, J Surg Oncol. 1998; 67: 194-202.
Ishida H, et al. Surg Today. 2003; 33 (12): 885-92.
Oberg A, et al, Anticancer Res. Mar.-Apr. 2000; 20 (2B): 1085-91.
Holten-Andersen et al. (Eur. J. Cancer. Aug. 2006; 42 (12): 1889-1896).
Tracy A. Plumpton et al.; Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum; Elsevier Science B.V.; pp. 137-154; 1995.
Zeng, Z.S. et al.; Abstract #2038: High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer, as determined by enzyme-linked immunosorbent assay (ELISA), correlate with poor outcome; Proceedings of the American Association for Cancer Research, vol. 39; p. 298; Mar. 1998.
Mads N. Holten-Andersen et al., “Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases I in Plasma by Immunoassay”,Clinical Chemistry48:8, 1305-1313 (2002).
Mads N. Holten-Andersen et al., “Total Levels of Tissue Inhibitor of Metalloproteinase 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer”,Clinical Cancer Research, vol. 8, 156-164, Jan. 2002.
Zhou, et al., “Identifying Markers for Pancreatic Cancer by Gene Expression Analysis,”Cancer Epidemiology, Biomarkers&Prevention, (1998), 7(2), 109-112.
Wood, et al., “In Situ Hybridization Studies Of Metalloproteinases 2 And 9 And TIMP-1 and TIMP-2 Expression In Human Prostate Cancer,”Clinical&Experimental Metastasis(1997), 15(3), 246-258.
Jung, et al., “Quantification Of Matrix Metalloproteinases And Tissue Inhibitors Of Metalloproteinase In Prostatic Tissue: Analytical Aspects”,Prostate, (1998), 34(2), 130-136, New York.
Naruo, et al., “Serum Levels of a Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) in Bladder Cancer Patients”,International Journal of Urology, Churchill Livingstone, Tokyo, JP, vol. 1, No. 3, Sep. 1994.
Zucker, et al., “Plasma Assay of Gelatinase B: Tissue Inhibitor of Metalloproteinase Complexes in Cancer,”Cancer, American Cancer Society, Philadelphia, PA, vol. 76, No. 9, Aug. 15, 1995.
Henriet, et al., “Tissue Inhibitors of Metalloproteinases (TIMP) in Invasion and Proliferation”,APMIS, Copenhagen, DK, vol. 107, No. 1, 1999.
National Library of Medicine, PubMed Website, “Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients”, Naruo S et al., Int J Urol, vol. 1, No. 3 Sep. 1994, pp. 238-231, see abstract.
National Library of Medicine, PubMed Website, “Tissue inhibitors of melloproteinase (TIMP) in invasion and proliferation”, Henriet P. et al., APMIS, vol. 109, No. 1, Jan. 1999, pp. 111-119, see abstract.
Patent Abstracts of Japan, JP8136548 A, Morinaga, May 31, 1996.
Dialog Information Services, File 159, Cancerlit, accession No. 93691448, Guillem JG et al., Evaluation of tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic marker of human colorectal cancer invation, Proc Annu Meet Am Assoc Cancer Res;34:A466 1993.
Dialog Information Services, File 159, Cancerlit, accession No. 96647008, “Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases” Clin Cancer Res; 1(8): 899-906, 1995, Zeng Z et al.
Tracy A. Plumpton et al.; Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum; Elsevier Science B.V.; pp. 137-154; 1995.
Zeng, Z.S. et al.; Abstract #2038: High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer, as determined by enzyme-linked immunosorbent assay (ELISA), correlate with poor outcome; Proceedings of the American Association for Cancer Research, vol. 39; p. 298; Mar. 1998.
Baker et al., “Serum Metalloproteinases and their inhibitors: Markers for Malignant Potential,” Br. J. Cancer 70:506-512 (1994).
Birkedal-Hansen et al., Matrix Metalloproteinases: A Review, Critical Reviews in Oral Biology and Medicine 4:197-250 (1993).
Clark et al., “Polyclonal and Monoclonal Antibodies Against Human Tissue Inhibitor of Metalloproteinases (TIMP) and design of an Enzyme-Linked Immunosorbent Assay to Measure TIMP,” Matrix 11:76-85 (1991).
Cooksley et al., “Immunoassays for the Detection of Human Collagenase, Stromelysin, Tissue Inhibitor of Metalloproteinases (TIMP) and Enzyme-Inhibitor Complexes,” Matrix 10:285-291 (1990).
Cooper et al., “Platelet-derived Collagenase Inhibitor: Characterization and Subcellular Localization,” Proc. Natl. Acad. Sci. USA 82:2779-2783 (1985).
DeClerck et al., “Inhibition of Invasion and Metastasis in Cells Transfected with an Inhibitor of Metalloproteinases,” Cancer Research 52:701-708 (1992).
Fujimoto et al et al., “A One-step Sandwich Enzyme Immunoassay for Tissue Inhibitor of Metalloproteinases-2 Using Monoclonal Antibodies,” Clinica Chimica Acta 220:31-45 (1993).
Goldberg et al., “Interaction of 92-kDa Type IV Collagenase with the Tissue Inhibitor of Metalloproteinases Prevents Dimerization, Complex Formation with Interstital Collagenase, and Activation of the Proenzyme with Stromelysin,” The Journal of Biological Chemistry 267:4583-4591 (1992).
Hembry et al., “
Brünner Nils
Christensen Ib Jarle
Holten-Andersen Mads Nikolaj
Nielsen Hans Jørgen
Hvidovre Hospital
Rawlings Stephen L.
Rigshospitalet
Roberts Mlotkowski & Hobbes PC
LandOfFree
Tissue inhibitor of matrix metalloproteinases type-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue inhibitor of matrix metalloproteinases type-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue inhibitor of matrix metalloproteinases type-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3957454